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E-mail address: jgroetzinger@biochem.uni-kiel.deA great number of physiological processes are regulated by the release of ectodomains of membrane
proteins. A Disintegrin And Metalloprotease 17 (ADAM17) is one of the important enzymes, which
mediate this process called shedding. Today, more than 70 substrates of this transmembrane metal-
loprotease are known. This broad spectrum raises the question how ADAM17 recognizes its sub-
strates speciﬁcally. Differently tagged ADAM17 deletion variants were used to demonstrate that
exclusively the extracellular domains of ADAM17 are needed for interaction with two of its sub-
strates, the IL-6R and the IL-1RII; whereas the transmembrane- and cytoplasmic-region are dispens-
able for this process. In the extracellular part solely the membrane-proximal domain of ADAM17 is
mandatory for recognition of the two type-I transmembrane proteins, but not for the interaction
with the type-II transmembrane molecule TNF-a.
Structured summary of protein interactions:
IL-6R physically interacts with ADAM17 by anti bait coimmunoprecipitation (View interaction) ADAM17
physically interacts with
IL-1RII by anti tag coimmunoprecipitation (View interaction)
 2012 Federation of European Biochemical Societies. Published by Elsevier B.V. All rights reserved.1. Introduction
ADAM17 (A Disintegrin And Metalloprotease 17) is involved in
many physiological processes, including cell migration and prolifer-
ation. More than 70 substrates of ADAM17 are described so far [1].
These substrates include pro-inﬂammatory cytokines and cytokine
receptors, like Tumor Necrosis Factor-a (TNF-a) [2,3], interleukin-6
receptor (IL-6R) [4] and IL-1RII [5], which are proteolytically cleaved
and released from the membrane, a process named ectodomain
shedding. This does not only provide a possibility for protein
down-regulation but also for initiating or inhibiting autocrine and
paracrine signaling via soluble proteins. Gene disruption ofchemical Societies. Published by E
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(J. Grötzinger).ADAM17 inmice leads to perinatal lethality, highlighting the impor-
tance of ectodomain shedding [6].
Members of the ADAM-family are type-I transmembrane multi-
domain metalloproteases consisting of an N-terminal signal
peptide, a pro-, a catalytic-, a disintegrin-, a cysteine-rich- and an
Epidermal Growth Factor- (EGF-) like-domain followed by a single
transmembrane region and a cytoplasmic tail. It is described that
the cytoplasmic domain of ADAM17 is involved in regulatory events
like protein trafﬁcking [7], but is not needed for phorbol 12-myris-
tate 13-acetate (PMA) or src induced shedding [5,8]. Furthermore,
the transmembrane region of ADAM17 is necessary for shedding
of Transforming Growth Factor-a and TNF-a, since coupling of the
extracellular part of ADAM17 to the plasma membrane by a glyco-
sylphosphatidylinositol (GPI) anchor leads to a loss of shedding
activity [9]. ADAM10 and ADAM17 are atypical members of the
ADAM-family; they contain a pro-, a catalytic-, a disintegrin- and
a membrane-proximal domain (MP) with a novel a/b fold.
(Fig. 1A) [10–12]. The extracellular part of mature ADAM17 most
likely adopts a C-shaped conformation [11,13], thereby localizing
the membrane-proximal domain close to the active site. Thislsevier B.V. All rights reserved.
Fig. 1. Expression of ADAM17 deletion variants. (A) A schematic drawing of ADAM17. (B–E) Schematic pictures of each construct are depicted in the ﬁrst row. Expression
analysis by Western blotting and ﬂow cytometry analysis is shown in the second and third column, respectively. The used antibody for Western blot analysis is indicated. The
left lane of the Western blots shows the sample of interest, whereas the right lane shows the corresponding control. Flow cytometry was performed using the antibody A300E
(see Materials and methods) and demonstrates that all constructs are expressed on the cell surface (red: non-transfected cells; blue: transfected cells).
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involved in substrate recognition and enzyme activation [5,11,13–
17]. Here we show that the membrane-proximal domain of
ADAM17 is the minimal requirement for recognizing two type-I
transmembrane substrates, IL-1RII and IL-6R, but not for the
type-II transmembrane protein TNF-a.
2. Materials and methods
2.1. Cloning of ADAM17 variants and substrates
Murine full-length ADAM17, murine full-length chimera of
ADAM17 and ADAM22 (ADAM17-EGF22), deletion variants ofhuman ADAM17 and human N-terminally tagged substrates were
cloned using standard procedures. Detailed information about
the constructs is provided in Supplementary Fig. 1. Oligonucleo-
tides used for insert ampliﬁcation and insertions of the respective
tags are listed in Supplementary data Table S1.
2.2. Cells and transfection
HEK-293 cells and ADAM17ex/ex mEFs were cultured in DMEM
high-glucose containing 10% fetal calf serum (FCS), penicillin (60 mg/
l) and streptomycin (100 mg/l) (PAALaboratories,Marburg,Germany).
Transfectionwas performed using TurboFect (Fermentas, St. Leon-Rot,
Germany) according to manufacturer’s instructions.
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Co-immunoprecipitation experiments and Western blotting were
performed as described earlier [18,19] and in the Supplementary data.
Depending on the constructs, rabbit anti-HA- (C29F4), rabbit anti-
FLAG- (M2), rabbit anti-myc- (71E10), rabbit anti-TNF-a, rabbit anti-
caveolin-1 (D46G3), murine anti-myc- (New England, Biolabs – Cell
Signaling, Germany) or murine anti-PC- (HPC4), anti-IL-6R- as well
as amurine anti-ADAM17 antibody directed against its disintegrin do-
main (A300) [20] were used. To avoid the appearance of heavy and
light chain in the blots of immunoprecipitated samples a combination
of murine anti-PC- or anti-IL-6R-antibodies and rabbit derived anti-
bodies was used. In case of ADAM17-GPI two antibodies of murine
origin were used, since the HA-tagged variant could not be expressed.
When anti-PC-tag antibody was applied, buffers were supple-
mented with 4 mM CaCl2; lysis buffer contained 20 mM Tris/HCl
pH 7.6, 150 mMNaCl, 2 mM EDTA, 1% Triton X-100 and ‘‘complete’’
protease inhibitor mixture without EDTA (Roche applied science,
Mannheim, Germany).
2.4. Shedding assay
HEK-293 cells were transfected with plasmids coding for the
respective substrates and ADAM17 variants at a ratio of 1:10. As
substrate either humanAP-IL-6R or humanAP-IL-1RIIwere used. Next
day, medium was replaced by DMEM high-glucose. Cells were either
left untreated, stimulated with 100 nM PMA (Merck, Darmstadt,
Germany) or stimulated with 100 nM PMA and treated with 50 lM
metalloprotease inhibitor GM6001 (Millipore, Schwalbach/Ts.,
Germany). After 2 h, supernatant and cells were harvested. For detec-
tion of cell associated AP activity, cells were lysed in lysis buffer as de-
scribed above, andmixed, like the supernatant, with the same volume
of substrate solution [100 mM glycine, 1 mM MgCl2 and 1mM ZnCl2
containing 1mg/ml p-nitrophenylphosphate (Sigma, Taufkirchen,
Germany)] and absorption was measured at 405 nm. The absorption
of the supernatant was divided by the absorption of cell lysate and
the ratio normalized against the respective sample treated with PMA
and metalloprotease inhibitor. Student’s t-test was performed using
http://www.physics.csbsju.edu/stats/t-test.html.
2.5. ADAM17 activity assay
ADAM17ex/ex mEFs [23] were transfected either with constructs of
murine ADAM17, the murine ADAM17-EGF22 chimera or peGFPN1
(as mock) and AP-IL-1RII in an 1:5 ratio. One day after transfection
media was replaced and cells treated like in the shedding assays with
the exception that instead of 50 lM GM6001 10 lM marimastat
(Merck, Darmstadt, Germany) was used to inhibit metalloprotease
activity. After 2 h medium and cells were harvested and analyzed for
AP activity as described for the shedding assay.
2.6. Flow cytometry
HEK-293 cells were harvested two days after transfection [20].
For detection of ADAM17 variants, 2 lg/ml of A300E antibody, di-
rected against the membrane-proximal domain of ADAM17, were
used to stain one million cells [20].
3. Results
3.1. Construction and cell surface expression of ADAM17 variants
To gain insight into the function of the non-catalytic extracellu-
lar domains of ADAM17 the full-length molecule as well as
deletion variants thereof were analyzed for substrate binding byco-immunoprecipitation experiments. Therefore ADAM17 variants
were tagged and expressed in HEK-293 cells (Fig. 1 and Supple-
mentary Fig. 1A).
The murine full-length ADAM17 was C-terminally tagged either
with a FLAG- (Fig. 1B), an HA- or PC-tag (data not shown) (Supple-
mentary Fig. 1A). To analyze the impact of the transmembrane-
and the cytoplasmic region for substrate recognition a construct
which lacks these parts was used. Thereby the extracellular region
of murine ADAM17 (amino-acid residue 1 to 657 of the native
ADAM17 sequence) was fused to a GPI-membrane anchor
(ADAM17-GPI, Fig. 1C). ADAM17-GPI comprises all domains of its
extracellular part and contains a myc- as well as a PC-tag between
its coding sequence and the GPI attachment sequence (Supplemen-
tary Fig. 1A). To reduce a part of the artiﬁcial elongation resulting by
the insertion of the two tags, amino acid 658–671 of the extracellu-
lar region was deleted.
To examine if the catalytic domain is needed for substrate rec-
ognition, a GPI-variant without this domain, DCat-ADAM17-GPI,
was cloned (Fig. 1D and Supplementary Fig. 1A). Therefore human
DCat-ADAM17 [21] was used as template to generate a construct
which starts with the human IL-6 signal peptide followed by the
coding sequence of human ADAM17 from amino-acid residue
475 (Supplementary Fig. 1A).
To distinguish between the roles of the disintegrin- and mem-
brane-proximal-domain the disintegrin domain of DCat-ADAM17-
GPIwas deleted resulting in a constructwhich encodes only amem-
brane bound membrane-proximal domain starting from amino-
acid residue 581 of the native ADAM17 sequence (MPD17-GPI,
Fig. 1E and Supplementary Fig. 1A). DCat-ADAM17-GPI as well as
MPD17-GPI was obtained by replacing the murine ectodomain of
ADAM17-GPI with the respective inserts. For co-immunoprecipita-
tion experiments with the IL-6R, where antibodies from murine
origin had to be used for precipitating the receptor, the PC-tag of
the GPI constructs was replaced by an HA-tag (data not shown), to
give the possibility of using antibodies from non-murine origin. As
depicted in Fig. 1 all variants could be expressed in HEK-293 cells
and were located at the cell surface as demonstrated by Western
blotting and ﬂow cytometry, respectively.
3.2. Determination of ADAM17 domains involved in substrate
recognition
For co-immunoprecipitation of ADAM17 with the human IL-6R
as substrate a very sensitive monoclonal antibody against this
transmembrane type-I protein was used. As shown in Fig. 2A, this
antibody was able to pull-down the IL-6R and full-length ADAM17
was co-precipitated. Since the transmembrane- and the cytoplas-
mic-region are important for the regulation and the function of this
enzyme [7,9,22] we tested whether these regions are mandatory
for substrate binding using the GPI anchored variant comprising
the extracellular part of murine ADAM17 (Fig. 1C). As shown in
Fig. 2B this variant could be precipitated by the human IL-6R dem-
onstrating that the cytoplasmic- and transmembrane-region are
not crucial for substrate recognition. The same result was obtained
with a corresponding variant lacking the catalytic domain, DCat-
ADAM17-GPI. The co-precipitation of DCat-ADAM17-GPI with
the IL-6R implicates that the catalytic domain is also dispensable
for binding of the IL-6R (Fig. 2C).
Previous work suggested that the disintegrin domain has scaf-
folding functions and places its neighboring domains in a correct
orientation relative to each other [13], whereas the membrane-
proximal domain is thought to be involved in substrate recogni-
tion. Accordingly, the IL-6R precipitated MPD17-GPI (Fig. 2D), the
construct containing solely the membrane anchored membrane-
proximal domain, suggesting that the membrane-proximal domain
alone is sufﬁcient for substrate binding.
Fig. 2. The membrane-proximal domain of ADAM17 recognizes the IL-6R. HEK-293 cells were co-transfected with human IL-6R and different ADAM17 variants. Three days
later cells were harvested, lysed and subjected to co-immunoprecipitation experiments, thereby the IL-6R was precipitated. (A) Precipitation of the receptor leads to a pull-
down of full-length ADAM17, which could be detected by its HA-tag. (B-D) Deletion of the transmembrane domain and the cytoplasmic region, using GPI anchored proteins,
does not inhibit these effects; as shown for the ectodomain detected by its PC-tag (B), DCat-ADAM17-GPI (C) as well as for MPD17-GPI (D) both detected by their HA-tag.
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experiments with a second substrate, the IL-1RII. This time not
the substrate, but ADAM17 or its variants, were precipitated. In
the ﬁrst immunoprecipitation an HA-tagged full-length ADAM17
was chosen, because the FLAG-tagged variant could not be precip-
itated using the respective antibody. Immunoprecipitation of full-
length ADAM17 leads to co-precipitation of the N-terminally
myc-tagged IL-1RII (Fig. 3A and Supplementary Fig. 1B). Further-
more a precipitation of DCat-ADAM17-GPI as well as MPD17-GPI,
via their PC-tag, co-precipitates the IL-1RII (Fig. 3B and C). The
GPI constructs were, according to their second tag, the myc-tag,
detectable by anti-myc antibodies in the respective blots (Fig. 3B
and C).
To rule out the possibility that endogenous ADAM17 interferes
with the co-immunoprecipitation experiments, we used ADA-
M17ex/ex mEFs generated from ADAM17ex/ex mice [23] in which
ADAM17 expression is reduced more than 95%. These cells were
co-transfected with vectors coding for the IL-6R and MPD17-GPI.
Although the expression level was low (the substrate could not
be detected in the input control) pull-down of the IL-6R lead to
an accumulation of the protein, which co-precipitated the
HA-tagged MPD17-GPI (Fig. 3D) conﬁrming that the membrane-
proximal domain is the minimal requirement for substrate
binding.
ADAM17 is located and active within lipid rafts [24]. To exclude
the possibility that whole lipid rafts were precipitated, we probed
against caveolin-1 as a marker for lipid rafts (Fig. 3E). In this exper-
iment caveolin-1 could only be detected in the input control but
not in the lanes loaded with the immunoprecipitated sample. For
this experiments a new lot of marker was used, which runs lower
than the lot used before, therefore all bands appear a little too high.
For example MPD17-GPI appears in the experiments above just be-
low 26 kDa and is shifted now towards to 26 kDa; and caveolin-1,
which should appear at 21–24 kDa, is detected little above 26 kDa.Additional co-immunoprecipitation experiments of MPD17-GPI
together with humane TNF-a show the same shift in size, whereby
proTNF-a (25 kDa) runs between 26 and 34 kDa. Interestingly,
pull-down of the PC-tagged variant of ADAM17 leads not to a co-
precipitation of pro-TNF-a (Fig. 3F), indicating that the co-precipi-
tation experiments are speciﬁc and not due to overexpression arti-
facts. In addition this result shows that the membrane-proximal
domain is most likely not the minimal module for recognizing
the type-II transmembrane protein TNF-a.
3.3. Inﬂuence of ADAM17 variants on the activity of endogenous
ADAM17
It was described that DCat-ADAM17 acts as an inhibitor of
ADAM17 [25]. If this effect is due to competition of DCat-ADAM17
with the wild-type molecule for substrates, the same effect should
be true for all variants which contain the membrane-proximal
domain. Hence, we performed shedding assays using AP-tagged
variants of IL-6R and IL-1RII as substrates (Supplementary Fig. 1B
and Fig. 4). In addition to DCat-ADAM17-GPI, a construct compris-
ing the transmembrane domain but lacking the cytoplasmic por-
tion (DCat-ADAM17Dcyto, Supplementary Fig. 1A) was tested to
analyze the inﬂuence of the transmembrane region. Both PC-
tagged ADAM17 variants, DCat-ADAM17Dcyto and DCat-
ADAM17-GPI, signiﬁcantly inhibit shedding of the IL-6R and the
IL-1RII in a comparable range (<0.001, 0.003 and P = 0.017,
P = 0.003, Fig. 4A). Accordingly the described inhibitory property
of DCat-ADAM17 is most probably located in its extracellular part
and there is no detectable contribution of the transmembrane
domain.
The same inhibitory effect is observed if the disintegrin domain
is missing and only the membrane-proximal domain is anchored to
the membrane (MPD17-GPI). Co-transfection of MPD17-GPI with
IL-6R or IL-1RII leads to a signiﬁcant decrease in their release from
Fig. 3. The membrane-proximal domain of ADAM17 is the minimal requirement for substrate recognition. Full-length ADAM17 (A) as well as DCat-ADAM17-GPI (B) and
MPD17-GPI (C) were able to precipitate myc-tagged IL-1RII. (B, C) The PC-tagged deletion variants were pulled down using anti-PC-tag antibodies. Due to the presence of the
second tag within the GPI-constructs (a myc-tag) both proteins ADAM17 variant and IL-1RII could be detected using rabbit anti-myc antibody as depicted by the arrows. (D)
ADAM17ex/ex mEFs were transfected with IL-6R and MPD17-GPI containing an HA-tag. The IL-6R was precipitated and both proteins could be detected. (E) HEK-293 cells were
co-transfected with IL-6R and MPD17-GPI. Similar to Fig. 2D pull-down of the substrate leads to a co-precipitation of the HA-tagged membrane anchored membrane-
proximal domain. The blot was additionally probed for caveolin-1 as a marker for lipid rafts. (F) Pull-down of MPD17-GPI by its PC-tag from lysate of HEK-293 cells co-
transfected with human TNF-a and MPD17-GPI leads to no precipitation of the substrate.
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Fig 4A). Interestingly, also the soluble expressed membrane-prox-
imal domain reveals, despite its low expression, a slight but signif-
icant inhibition of IL-1RII shedding (Supplementary Fig. 2A). The
poor expression of the soluble domain becomes apparent by
Western blotting. All membrane bound ADAM17 variants could
be detected by Western blotting against their PC-tags after one
day of transfection (Fig. 4B and C). This proof could not be achieved
in case of the soluble membrane-proximal domain; its expression
could only be detected in an independent experiment after three
days of expression. Therefore these results support the importance
of the membrane-proximal domain in the recognition of the two
type-I transmembrane proteins.3.4. Activity of ADAM17-EGF22 chimeric molecules
To further validate that the membrane-proximal domain of
ADAM17 is essential for substrate recognition this domain was
replaced by a different domain. Hence a chimeric molecule was
generated by replacing solely the membrane-proximal domain of
murine PC-tagged ADAM17 by the EGF-like domain of murine
ADAM22 (ADAM17-EGF22, Supplementary Fig. 1A). The proteo-
lytic activity of ADAM17-EGF22 was tested by co-transfecting
ADAM17ex/ex mEFs with this constructs and AP tagged IL-1RII
and compared with wild-type ADAM17. The activity of the wild-
type molecule could be stimulated by the addition of 100 nM
PMA (Fig. 5A). In contrast, the measured activity of the chimeric
Fig. 4. Inhibition of ADAM17 mediated shedding is most prominent by the
membrane bound membrane-proximal domain. HEK-293 cells were co-transfected
with AP-tagged IL-1RII or IL-6R and ADAM17 variants containing a PC-tag. One day
after transfection, medium was changed and cells were left untreated, stimulated
with PMA alone or stimulated with PMA in the presence of a metalloprotease
inhibitor (GM6001). Two hours later, supernatants and cells were harvested. (A) AP
activity was measured in the supernatant as well as in the cell lysate. The ratios of
activities (supernatant/lysate) were normalized against the sample treated with
PMA and metalloprotease inhibitor. P-values below 0.05 are considered as
statistically signiﬁcant and marked with one asterisk (⁄); values below 0.01 are
labeled with two and below 0.001 with three asterisks. (B–C) Expression of the
ADAM17 variants was conﬁrmed by Western blots against their PC-tag for
experiments regarding the IL-1RII (B) and IL-6R (C).
Fig. 5. The ADAM17-EGF22 chimera is catalytically inactive. ADAM17ex/ex mEFs
were co-transfected either with murine wild-type ADAM17, ADAM17-EGF22 or
peGFPN1 (mock) and AP-tagged IL-1RII. After 24 h the medium was exchanged and
cells were either left untreated, stimulated by the addition of 100 nM PMA or
stimulated in the presence of a 10 lM marimastat. After 2 h supernatants and cells
were harvested. (A) AP activity in the supernatant and in cell lysates was
determined and their ratios were normalized against the sample treated with
marimastat. Data are mean values from at least four independent experiments.
Comparison of the PMA treated samples (ADAM17:ADAM17-EGF22 and ADAM17:-
mock) are statistically signiﬁcant (P-value <0.0001). (B) Expression of murine
ADAM17 and murine ADAM17-EGF22, both PC-tagged, were tested by Western
blotting using an a-PC antibodies.
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mock control. Fig. 5B conﬁrms the expression of the wild-type and
ADAM17-EGF22 chimera by Western blotting using their PC-tag.
These results clearly demonstrate that the chimeric ADAM17-
EGF22 is inactive and conﬁrmed the importance of the mem-
brane-proximal domain of ADAM17 in substrate recognition.
4. Discussion
The aim of this work was to understand the role of the extracel-
lular domains of ADAM17 in substrate recognition. Therefore, dif-
ferent deletion variants of ADAM17 were constructed and their
expression was analyzed by Western blotting and ﬂow cytometry
analysis (Fig. 1). Comparison of the ﬂow cytometry measurements
suggests that the construct containing the whole intracellular part
of ADAM17 was expressed at the cell surface to a lesser degree
than the GPI anchored variants, which is in agreement with the
ﬁnding that in unstimulated cells most ADAM17 is localized within
the cell [7].
First, co-immunoprecipitation experiments of murine full-
length ADAM17 with human substrates were performed (Fig. 2A
and Fig. 3A). Species difference of enzyme and substrate in case
of the IL-6R is in agreement with the ﬁndings of Garbers et al.
[26] who demonstrated that human IL-6R is not only a substratefor human ADAM17 but also for murine ADAM17, whereas murine
IL-6R is not.
Overexpression of full-length ADAM17 in HEK-293 leads to a
strong appearance of immature ADAM17, but hardly any detect-
able band of the mature enzyme (Fig. 1B). This disappearance
was explained by autoproteolysis of mature ADAM17 during cell
lysis [27]. But addition of a metalloprotease inhibitor (10 lM
marimastat) during and after cell-lysis did not change this phe-
nomenon. Additionally, the lack of the mature form of ADAM17
seems to be unique for strong overexpression, since expression of
the same constructs in ADAM17ex/ex mEFs reveals both forms (data
not shown). The absence of the mature form might be due to an
overload of the ER/Golgi transport, an impaired maturation in the
Golgi apparatus, a rapid degradation of the mature form or the
concentration of metalloprotease inhibitor during lysis was too
low. Interestingly, co-transfection and/or co-precipitation of full-
length ADAM17 with its substrates leads to an accumulation of
the mature form implicating its stabilization or an enhanced mat-
uration (Fig. 2A and 3A).
The appearance of both ADAM17 forms in the co-immunopre-
cipitation experiments is somewhat surprising, since the mature
form is the catalytically active one. Enzyme and substrate might
meet already in the secretory pathway, which is even more likely
in case of overexpression. Under these conditions it is conceivable
that the pro-domain does not interfere with the interaction be-
tween the enzyme and the substrates.
To analyze the minimal structural requirement for substrate
binding, additional co-precipitation experiments with deletion
mutants were performed. Deletion of the transmembrane- and
cytoplasmic-region by anchoring the extracellular part to the
membrane by GPI (Fig. 1C) does not abolish its interaction with
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cytoplasmic-region is needed for substrate recognition. This is sup-
ported by the ﬁnding that both molecules (DCat-ADAMDcyto and
DCat-ADAM-GPI) inhibit the proteolytic activity of the wild-type
molecule to the same extent (Fig. 4A). Though, it does not exclude
that the transmembrane- and cytoplasmic-region have accessory
functions and that the transmembrane region ensures a correct ori-
entation of the extracellular domains. This is supported by the
observation that a variant of ADAM17 attached to the plasma
membrane by a GPI anchor is proteolytically inactive [9], whereas
ADAM17 lacking only the cytoplasmic portion is active [5].
Variants lacking the catalytic- (DCat-ADAM17-GPI) or addition-
ally the disintegrin-domain (MPD17-GPI) were both able to bind
IL-6R and IL-1RII (Fig. 2C, D and 3B–E), corroborating that solely
the membrane-proximal domain is needed for substrate binding
and that neither the catalytic- nor the disintegrin-domain is essen-
tial for this purpose. The importance of the membrane-proximal
domain in substrate recognition is in agreement with reports from
Tape et al. and Reddy et al., who demonstrated that blockade of the
non-catalytic extracellular domains leads to reduced shedding
activity [17] and that the membrane-proximal domain of ADAM17
is essential for shedding of the IL-1RII [5].
The latter observation could be veriﬁed with the ADAM
17-EGF22 chimeric molecule, which is completely inactive. Similar
results were obtained using a ‘‘cat-dis ADAM17/EGF ADAM-10B’’
chimera by Reddy et al. [5]. The two chimera differ in two main as-
pects, ﬁrst the choice of the domain borders and second in the
presence/absence of the cytoplasmic tail.
Thedomainborders ofADAM17-EGF22arebasedon thepreviously
published structures of ADAM10 [11] and ADAM22 [12]. Hence the
disintegrin and membrane-proximal domains of ADAM17 are sepa-
rated between residue 580 and 581, which differs only slightly from
the ADAM17-ADAM10B chimera of Reddy et al., where the cut is lo-
cated between 573 and 574 [5] and proceeded by the corresponding
ADAM10 sequence, but lacking the cytoplasmic tail [5]. In contrast,
in the ADAM17-EGF22 chimera solely the membrane-proximal do-
main was replaced (Supplementary Fig. 1A). The exclusive and exact
exchange of the membrane-proximal domain results in an ADAM17-
EGF22 chimera which still comprises the amino-acid residues located
C-terminal to this domain, including the unstructured stalk region as
well as the transmembrane region and cytoplasmic tail of ADAM17.
Therefore the loss of activity in the ADAM17-EGF22 chimera is exclu-
sively due to the exchange of themembrane-proximal domain andnot
to an alteration in the regions located C-terminally of the membrane-
proximal domain.
Differences in the localization of the chimera within microdo-
mains of the plasma membrane should be considered since
ADAM17 is known to be located in lipid rafts [24], whereas
ADAM10 is supposed to be a non-raft protein [28]. The presence
of the C-terminal parts downwards from the membrane-proximal
domain of ADAM17, e.g. the transmembrane region, might ensure
a proper sorting of ADAM17-EGF22 to the lipid rafts.
The second difference between the two molecules is the pres-
ence of the cytoplasmic tail in ADAM17-EGF22 which is absent
in ADAM17-ADAM10B [5]. For both proteases [22,29] it has been
suggested that steric hindrances within the cytoplasmic region is
a regulatory property of these enzymes, resulting in a reduced
activity by lowering the accessibility of the proteases to their sub-
strates. Whereas ADAM17-EGF22 is completely inactive minor
shedding activity was detected for ADAM17-ADAM10B [5]. This
might be due to the absence of the cytoplasmic tail in ADAM17-
ADAM10B and consequently the loss of its inhibitor potential.
Nevertheless one should be careful comparing these data because
the performed shedding assays are different.
The demonstrated importance of the ADAM17membrane-prox-
imal domain for substrate recognition is further underlined by theﬁnding that not only constructs lacking the catalytic domain, but
also the disintegrin domain are able to inhibit shedding of the
wild-type molecule (Fig. 4A), as described for DCat-ADAM17 [25].
Furthermore, the soluble membrane-proximal domain is able to re-
duce the proteolytic activity of ADAM17 (Supplementary Fig. 2A).
The soluble membrane-proximal domain is expressed and secreted
at low levels and therefore the local concentration is expected to be
low, whereas the GPI anchored variant accumulates on the plasma
membrane. As a consequence, the GPI anchored membrane-proxi-
mal domain is more efﬁcient in inhibition than the soluble domain.
Further studies should clarify which amino-acid residues of the
membrane-proximal domain are involved in the interaction be-
tween substrate and enzyme. In addition, it would be interesting
to study whether this is a direct interaction or mediated by acces-
sory molecules.
The presented data demonstrate that the membrane-proximal
domain of ADAM17 is the minimal requirement for substrate rec-
ognition of type-I transmembrane proteins, like IL-1RII and IL-6R.
Interestingly, this does not hold true for TNF-a. This difference is
not unexpected, since distinct modes of processing for the type-II
transmembrane protein TNF-a and type-I transmembrane pro-
teins, like IL-6R, were described [30,31]. A peptide representing
the cleavage site of TNF-a is processed very efﬁciently by ADAM17,
whereas cleavage of the corresponding IL-6R peptide was not
detectable [31], implicating that two distinct mechanisms of recog-
nition exist; one independent of the non-catalytic extracellular do-
mains and one dependent on the membrane-proximal domain of
ADAM17. Further analysis should address the recognition of
type-II and GPI-anchored substrates and study if co-localization
within the cell is sufﬁcient for these proteins to be shed.
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